Refractory celiac disease

Refractory celiac disease (RCD) is a rare and serious complication of celiac disease in which symptoms of malabsorption and villous atrophy of the small intestine persist or recur despite strict adherence to a gluten-free diet for at least 12 months. It is classified into two subtypes: Type I (RCD-I), in which intraepithelial lymphocytes appear normal, and Type II (RCD-II), characterized by an aberrant clonal population of intraepithelial lymphocytes that lack normal surface T-cell markers. RCD-II is considered a pre-lymphomatous condition with a significant risk of progression to enteropathy-associated T-cell lymphoma (EATL), a serious and often fatal malignancy. The disease primarily affects the gastrointestinal system, particularly the small intestine, leading to chronic diarrhea, severe malabsorption, weight loss, abdominal pain, and nutritional deficiencies including iron deficiency anemia, vitamin deficiencies, and hypoalbuminemia. Patients may also experience fatigue, bone disease (osteoporosis), and general debilitation. Because the condition does not respond to dietary gluten exclusion alone, it can lead to progressive deterioration of nutritional status and quality of life. Treatment of RCD-I typically involves immunosuppressive therapies such as corticosteroids (budesonide or prednisone), azathioprine, or other immunomodulators, and many patients respond favorably. RCD-II is more difficult to manage and carries a poorer prognosis. Treatment options for RCD-II may include cladribine, autologous stem cell transplantation in selected cases, and close surveillance for lymphoma development. Nutritional support, including parenteral nutrition when necessary, is an important component of management. Novel therapies are under investigation, but no universally effective treatment for RCD-II currently exists.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Refractory celiac disease